Pathological evaluation confirmed residual invasive ductal carcinoma within the breast tissue (ER- and PgR-negative, HER2 3+) and metastatic carcinoma within three dissected axillary lymph nodes. This evidence concerns the gene ERBB2 and invasive ductal breast carcinoma.